After finishing at $23.41 in the prior trading day, Fulgent Genetics Inc (NASDAQ: FLGT) closed at $22.56, down -3.61%. In other words, the price has decreased by -$0.85 from its previous closing price. On the day, 594704 shares were traded.
Ratios:
Our goal is to gain a better understanding of FLGT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.16. For the most recent quarter (mrq), Quick Ratio is recorded 8.95 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on December 07, 2023, initiated with a Neutral rating and assigned the stock a target price of $35.
On December 08, 2022, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $65 to $40.
On November 18, 2022, Raymond James started tracking the stock assigning a Outperform rating and target price of $45.Raymond James initiated its Outperform rating on November 18, 2022, with a $45 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 when Xie Jian sold 22,000 shares for $26.52 per share. The transaction valued at 583,453 led to the insider holds 363,124 shares of the business.
Xie Jian sold 1,779 shares of FLGT for $49,053 on Dec 04. The President and COO now owns 385,124 shares after completing the transaction at $27.57 per share. On Dec 04, another insider, Kim Paul, who serves as the CFO and Treasurer of the company, sold 1,437 shares for $27.57 each. As a result, the insider received 39,623 and left with 200,460 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FLGT now has a Market Capitalization of 693.41M and an Enterprise Value of 228.50M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.31 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at 0.79 whereas that against EBITDA is -3.39.
Stock Price History:
Over the past 52 weeks, FLGT has reached a high of $44.09, while it has fallen to a 52-week low of $22.70. The 50-Day Moving Average of the stock is 26.70, while the 200-Day Moving Average is calculated to be 30.88.
Shares Statistics:
The stock has traded on average 209.70K shares per day over the past 3-months and 309.78k shares per day over the last 10 days, according to various share statistics. A total of 29.44M shares are outstanding, with a floating share count of 19.17M. Insiders hold about 35.31% of the company’s shares, while institutions hold 48.86% stake in the company. Shares short for FLGT as of Feb 15, 2024 were 517.24k with a Short Ratio of 2.47, compared to 508.24k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.75% and a Short% of Float of 3.10%.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.3, while EPS last year was -$0.22. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.17 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$0.77 and -$1.22 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$0.65, with 3 analysts recommending between -$0.2 and -$1.21.
Revenue Estimates
3 analysts predict $68.8M in revenue for the current quarter. It ranges from a high estimate of $74.8M to a low estimate of $64.17M. As of the current estimate, Fulgent Genetics Inc’s year-ago sales were $66.17M, an estimated increase of 4.00% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $72.3M, an increase of 6.60% over than the figure of $4.00% in the same quarter last year. There is a high estimate of $76.6M for the next quarter, whereas the lowest estimate is $68.18M.
A total of 3 analysts have provided revenue estimates for FLGT’s current fiscal year. The highest revenue estimate was $302.9M, while the lowest revenue estimate was $279.77M, resulting in an average revenue estimate of $287.59M. In the same quarter a year ago, actual revenue was $289.21M, down -0.60% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $333.55M in the next fiscal year. The high estimate is $350.6M and the low estimate is $310.55M. The average revenue growth estimate for next year is up 16.00% from the average revenue estimate for this year.
